menu
    • menu
    [{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Tonabacase","moa":"Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"iNtRON Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"iNtRON Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"iNtRON Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Enzyme","year":"2018","type":"Inapplicable","leadProduct":"Tonabacase","moa":"Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"iNtRON Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"iNtRON Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"iNtRON Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Enzyme","year":"2023","type":"Licensing Agreement","leadProduct":"Tonabacase","moa":"Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"iNtRON Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"iNtRON Biotechnology \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"8","companyTruncated":"iNtRON Biotechnology \/ Basilea Pharmaceutica"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Enzyme","year":"2023","type":"Licensing Agreement","leadProduct":"Tonabacase","moa":"Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"iNtRON Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"iNtRON Biotechnology \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"8","companyTruncated":"iNtRON Biotechnology \/ Basilea Pharmaceutica"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Enzyme","year":"2017","type":"Inapplicable","leadProduct":"Tonabacase","moa":"Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"iNtRON Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iNtRON Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"iNtRON Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"iNtRON Biotechnology","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Enzyme","year":"2023","type":"Licensing Agreement","leadProduct":"Tonabacase","moa":"Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"iNtRON Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iNtRON Biotechnology \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"8","companyTruncated":"iNtRON Biotechnology \/ Basilea Pharmaceutica"},{"orgOrder":0,"company":"Lysovant","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Tonabacase","moa":"Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Lysovant","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lysovant \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lysovant \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Tonabacase

    Menu

    Tonabacase

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            iNtRON Biotechnology

                            South Korea arrow
                            VMX
                            Not Confirmed

                            iNtRON Biotechnology

                            South Korea arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tonabacase

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Basilea Pharmaceutica

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Basilea Announces Exclusive License and Option Agreement for Potential First-In-Class Clinical-Stage Antibacte...

                            Details : Upon successful completion of the preclinical evaluation phase, Basilea will have the exclusive option to license LSVT-1701 (tonabacase) for further clinical development and commercialization.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            October 31, 2023

                            Lead Product(s) : Tonabacase

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Basilea Pharmaceutica

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            iNtRON Biotechnology

                            South Korea arrow
                            VMX
                            Not Confirmed

                            iNtRON Biotechnology

                            South Korea arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tonabacase

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Basilea Pharmaceutica

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Basilea Announces Exclusive License and Option Agreement for Potential First-in-class Clinical-Stage Antibacte...

                            Details : Under the agreement, Basilea will investigate SAL200 (tonabacase), a potential first-in-class clinical-stage antibacterial of the endolysin class, against methicillin-resistant and methicillin-susceptible Staphylococcus aureus.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            October 31, 2023

                            Lead Product(s) : Tonabacase

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Basilea Pharmaceutica

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            iNtRON Biotechnology

                            South Korea arrow
                            VMX
                            Not Confirmed

                            iNtRON Biotechnology

                            South Korea arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tonabacase

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Basilea Pharmaceutica

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            iNtRON, Executes Evaluation License and Option Agreement for SAL200

                            Details : Under the agreement, iNtRON grants Basilea exclusive right for preclinical evaluation of the antibacterial bio-drug N-Rephasin SAL200 (tonabacase), a novel endolysin-based anti-staphylococcal drug formulated for injection.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            October 30, 2023

                            Lead Product(s) : Tonabacase

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Basilea Pharmaceutica

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lysovant

                            Country arrow
                            VMX
                            Not Confirmed

                            Lysovant

                            Country arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tonabacase

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis

                            Details : Tonabacase is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Bacteremia.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            April 14, 2022

                            Lead Product(s) : Tonabacase

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            iNtRON Biotechnology

                            South Korea arrow
                            VMX
                            Not Confirmed

                            iNtRON Biotechnology

                            South Korea arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tonabacase

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety, PK, PD, Immunogenicity of N-Rephasin® SAL200 in Healthy Male Volunteers

                            Details : N-Rephasin (Tonabacase) is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Methicillin-Resistant Staphylococcus aureus.

                            Product Name : N-Rephasin

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            February 26, 2018

                            Lead Product(s) : Tonabacase

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            iNtRON Biotechnology

                            South Korea arrow
                            VMX
                            Not Confirmed

                            iNtRON Biotechnology

                            South Korea arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tonabacase

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase IIa Clinical Study of N-Rephasin® SAL200

                            Details : N-Rephasin (Tonabacase) is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Staphylococcal Infections.

                            Product Name : N-Rephasin

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            March 24, 2017

                            Lead Product(s) : Tonabacase

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            iNtRON Biotechnology

                            South Korea arrow
                            VMX
                            Not Confirmed

                            iNtRON Biotechnology

                            South Korea arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tonabacase

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male...

                            Details : N-Rephasin (Tonabacase) is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Methicillin-Resistant Staphylococcus aureus.

                            Product Name : N-Rephasin

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            May 16, 2013

                            Lead Product(s) : Tonabacase

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.